Search
Clinician Ordering Portal
Scientific evidence
Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients
May 2016
Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).
Publication: Current Medical Research and Opinion
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma
Mar 2015
Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes.
Publication: Journal of Cutaneous Pathology
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy
Mar 2015
Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients.
Publication: Journal of the American Academy of Dermatology
Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions
Mar 2015
Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition.
Publication: Biomarkers in Medicine
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma
Jan 2015
Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS, DMFS, MSS, OS using Kaplan-Maier analysis.
Publication: Clinical Cancer Research